Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682493 | 0.75 | TSHR (0.36) | SMN1; SMN2POLBNPC1RAB9AL3MBTL1 | |
| SCHEMBL221953 | 0.73 | AKR1C3 (0.38) | SMN1; SMN2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL221637 | 0.71 | NPC1 (0.38) | SMN1; SMN2POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL1883397 | 0.70 | CYP3A4 (0.43) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL7759714 | 0.63 | — | — | |
| SCHEMBL173628 | 0.60 | F2 (0.46) | SMN1; SMN2POLBPKMALDH1A1MEN1 | |
| SCHEMBL18463797 | 0.60 | — | — | |
| SCHEMBL8970161 | 0.59 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTPKM | |
| SCHEMBL92008 | 0.59 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AMAPTPKM | |
| SCHEMBL7756006 | 0.57 | PKM (0.35) | SMN1; SMN2POLBMAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508183-B1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | US | disclosed |
| US-8318741-B2 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120115959-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-05-10 | — | — | US | disclosed |
| US-20120071485-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-03-22 | — | — | US | disclosed |
| US-8088773-B2 | Therapeutic compositions and methods | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115959-A1 | Therapeutic Compositions And Methods | PDE6C, PDE6H, PDE6D | SMN1; SMN2 315/4885POLB 3074/4885NPC1 1501/4885 |
| US-20120071485-A1 | Therapeutic Compositions And Methods | PDE6H, PDE6C, PDE6D | SMN1; SMN2 179/4885POLB 3479/4885NPC1 1199/4885 |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | SMN1; SMN2 179/4885POLB 3479/4885NPC1 1199/4885 |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | SMN1; SMN2 179/4885POLB 3479/4885NPC1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.